On Tuesday, Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was 4.55% up from the session before settling in for the closing price of $2.86. A 52-week range for MREO has been $2.53 – $5.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -25.00% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -53.57%. With a float of $142.11 million, this company’s outstanding shares have now reached $154.73 million.
In an organization with 33 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -107.44%, operating margin of -10462.41%, and the pretax margin is -11633.65%.
Mereo Biopharma Group Plc ADR (MREO) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Mereo Biopharma Group Plc ADR stocks. The insider ownership of Mereo Biopharma Group Plc ADR is 8.16%, while institutional ownership is 62.55%. The most recent insider transaction that took place on Sep 13 ’24, was worth 253,454. In this transaction Chief Executive Officer of this company sold 60,046 shares at a rate of $4.22, taking the stock ownership to the 808,921 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Executive Officer sold 28,611 for $4.47, making the entire transaction worth $127,968. This insider now owns 868,967 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -53.57% per share during the next fiscal year.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
You can see what Mereo Biopharma Group Plc ADR (MREO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.10.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.51 million. That was better than the volume of 1.42 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.94%. Additionally, its Average True Range was 0.25.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 9.09%, which indicates a significant decrease from 18.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.86% in the past 14 days, which was higher than the 61.11% volatility it showed in the past 100 days.
However, in the short run, Mereo Biopharma Group Plc ADR’s stock first resistance to watch stands at $3.07. Second resistance stands at $3.14. The third major resistance level sits at $3.25. If the price goes on to break the first support level at $2.89, it is likely to go to the next support level at $2.78. The third support level lies at $2.71 if the price breaches the second support level.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
There are 155,146K outstanding shares of the company, which has a market capitalization of 462.64 million. As of now, sales total 10,000 K while income totals -29,470 K. Its latest quarter income was 0 K while its last quarter net income were -15,000 K.
